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Abstract 
The purpose of the research was to study Finnish people's attitudes towards 
biomedical research and whether the research sponsor makes a difference to those 
attitudes. A survey questionnaire was sent to a random sample of 25–64 years old. 
Respondents had a positive attitude towards biomedical research and there were only 
small variations by population group. When asked whether one’s own clinical blood 
samples could be used in scientific biomedical research, 84 per cent of the 
respondents would allow it. The most important reasons for giving routinely collected 
samples to a biobank were altruistic. Attitudes were strongly dependent on the 
sponsor of the research. Domestic research was looked at more positively than 
international research. Whether research was made by a public or private actor had 
less impact. The results suggest that people want to be research participants to help 
such research of their own free will, and to choose whom they help. This has an 
impact on the way participants are informed, on the criteria used by ethics committees 
and other research regulators, and also on transparency and access to research results. 
Introduction 
A common ethics-based view of biomedical research participation, culminating in 
informed consent, is that participants' own interests are primary.2,3,4 For each 
participant, the expected benefit–harm ratio should be positive.5 Our experience of the 
advice on what information to give to the research subject as part of obtaining 
informed consent suggests that those building ethical norms assume that potential 
research subjects are interested mainly in their own well-being, and societal interests 
or research policy play less of a role. However, earlier literature on research 
participants’ reasons for joining medical research shows that the reasons are partly 
altruistic, though many also expect personal benefit and some feel it to be a duty to 
participate.6,7,8,9 
 
In intervention research that has a high risk of physical harm, the focus on subject's 
well-being in informed consent is crucial. However, medical research is often based 
on blood and tissue samples, images and written documents. Data or samples already 
collected either in routine clinical practice or for previous research may be used. In 
such research, physical harm for subjects is a lesser concern and the informed consent 
weighs personal ownership, privacy and altruistic interests against research and 
societal interests.10 
 
The motivation of participants to support research and participate has also been shown 
to be dependent on research sponsorship.11 Critchley has argued that people’s trust in 
publically funded research is greater, because of to a greater level of trust in publically 
 
 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2009, Vol.5, No.2, pp.67-79 
 
_____________    
 
Genomics, Society and Policy, Vol.5, No.2 (2009) ISSN: 1746-5354 
68
funded scientists as against privately-funded scientists.12 The public/private 
dichotomy is, however, increasingly problematic in biotechnology because of the 
blurring of the boundary between publically and privately sponsored research,13 
making the distinction between the two categories problematic. 
 
When the Finnish Ministry of Social and Health Affairs started to prepare a law 
governing biobanks, the Finnish Funding Agency for Technology and Innovation 
(TEKES) financed us to carry out a survey on laypeople's opinions of biobanks.14 
Data from that survey was used to investigate people's general attitudes towards 
biomedical research and whether the research sponsor made a difference to their 
attitudes. Specific attitudes towards biobanks and informed consent have already been 
reported,15 and determinants of people’s reasons for participating in research will be 
reported separately (Sihvo et al. 2010 unpublished manuscript). 
Methods 
A survey questionnaire was mailed to a random sample of Finnish-speaking residents 
in Finland aged between 25–64 (n=2400) in 2007. After one reminder, a total of 1192 
(50 per cent) responses were received. Four respondents without background 
information are excluded from this paper. The questionnaires did not ask for the 
respondent's name, although they contained a number that was used to identify non-
respondents for the second mailing of the questionnaire. 
 
The questionnaire was sent jointly in the name of STAKES (the National Research 
and Development Centre for Welfare and Health, now merged into the National 
Institute for Health and Welfare) and the Department of Sociology, University of 
Helsinki. The cover letter referred to the expert group in the Ministry of Social Affairs 
and Health and stated the purpose of the survey to be the mapping of citizens' 
opinions. The questionnaire contained 28 questions focusing on opinions about 
biobanks and on the use of blood and tissue samples. The key questions (translated by 
the authors) used in this paper are given in Appendix 1. 
 
Table 1. Background characteristics of the respondents by age, % 
 25-34 35-44 45-54 55-64 Total 










Basic education      
   < 9 yr  0.8 1.6 28.7 50.0 23.0 
   middle level  36.1 44.8 36.2 26.4 35.0 
   high school  62.6 52.5 34.2 23.48 41.0 
Gender: woman 62.45 59.1 53.0 53.9 56.5 
Have children 42.9 70.8 80.8 86.1 72.6 
Has worked in health 
field 
20.2 19.1 18.4 14.5 17.8 
Total 100 100 100 100 100 
 
The results were first analyzed by age-groups. Statistical significance was tested by 
chi-square or t-test, while logistic regression was used to study the results by gender 
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and education, adjusting for age; odds ratios and 95 per cent confidence intervals were 
calculated. Table 1 gives the background characteristics of the respondents. The 
distribution of education by age reflects the change in the national education system in 
the 1970s. Among the younger age groups, more women than men responded. 
 
Compared to the original random sample, respondents were relatively similar in 
regard to gender (women 51 per cent of the original sample, 57 per cent of the 
respondents) and age-structure (respectively 22 per cent and 20 per cent of those aged 
25–34; 24 per cent and 22 per cent of those aged 35–44; 27 per cent and 29 per cent of 
those aged 45–54; and 26 per cent and 29 per cent of those aged 55–64).  
Results 
General attitudes by age 
In an attitudinal question with five options ranging from mainly positive to mainly 
negative (see question 3 in the Appendix), most respondents said they had a positive 
or quite positive attitude towards biomedical research -see Table 2. The answers were 
very similar in different age groups. 
 
Table 2. Attitudes towards biomedical research and research regulation, by age, %a 
 25-34 35-44 45-54 55-64 Total p-value 
(number) (238) (257) (348) (345) (1188)  
(Q3) Positive attitude b 
towards, % 
      
   genetic research 92 88 89 87 89 .239 
   diagnostic research 96 96 96 92 95 .018 
   development of new     
     drugs 
97 97 96 97 97 .916 
   development of new 
     vaccines 
97 95 97 96 96 .428 
(Q5) Use of own clinical 
blood samples for 
researchc, yes, % 
82 82 84 85 84 .924 
(Q19) Duty to 
participate in biobanksd, 
yes, % 
19 26 29 33 27 .001 
(Q1) Is concept "ethics 
committee" familiar, 
yes, %  
53 64 51 52 54 .005 
a: Q = question number, questions are given in Appendix 
b: Positive + quite positive (alternatives 1+2) 
c: From a case description 
d: From a series of claims 
 
The questionnaire presented a hypothetical case enquiring about the use of one’s own 
blood sample collected during a clinical patient contact (see Appendix). We asked 
whether the person would allow that sample to be used in scientific research studying 
the health impact of genetic and other exposures. The research design was said to 
include anonymous (coded) analysis, register linkages and storing the data in a public 
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research institute. Of the respondents, 84 per cent would allow the sample to be used 
in research (Table 2). Only 6 per cent said they would not allow their sample to be 
used and 11 per cent did not know or did not answer. There was no variation by age. 
 
The respondents were asked whether, from a list of concepts and institutions, the 
concept of "ethics committee" was familiar. About half (55 per cent) had heard of an 
ethics committee (Table 2), but only 15 per cent said they knew of its functions. 
 
The questionnaire included a section about biobanks, giving a definition of a biobank 
(see Appendix). People's motivation to (potentially) participate in biomedical research 
was studied by a question on their most important reasons to allow their own routinely 
collected samples to be given to a biobank, which could then be used in research and 
to develop new treatment methods (question 15 in the Appendix). The most frequently 
endorsed reasons for giving permission to use the samples were ‘promotion of 
medicine’ (91 per cent) and ‘benefits for future generations’ (82 per cent). About half 
(52 per cent) expected ‘personal benefit’ (to learn their own risks). ‘For the sake of 
increasing the international competitiveness of Finnish researchers’ gained some 
support (29 per cent), but ‘promotion of business’ received hardly any (3 per cent). 
Nine per cent chose the option of thinking it to be a ‘duty’. The answers were similar 
by age, except for ‘helping Finnish researchers’, which gained popularity with 
increasing age (16 per cent in the youngest age group and 41 per cent in the oldest). 
 
A quarter (27 per cent) agreed with the claim that it was people's duty to give their 
sample to a national biobank, because it would benefit all people (question 19c in the 
Appendix - see Table 2). The rest said no (41 per cent), did not know or did not 
answer (32 per cent). Older people were more likely than younger people to agree that 
it was a duty to give their samples to a biobank (Table 2). 
 
Importance of the sponsor 
In regard to the hypothetical case, people were asked whether they would allow their 
samples to be used for research to develop new drugs or procedures in a joint 
development project with industry (question 6, Appendix): 75 per cent said yes (Table 
3). The proportions saying yes were very similar in the different age groups. Only 9 
per cent said explicitly "no" and the rest (16 per cent) could not take a stand. 
 
The respondents were asked for which type of research they would allow their 
samples held in a national biobank to be used (Question 17, Appendix). More people 
would allow their samples to be used for research in Finland than for international 
research (Table 3). There was little difference whether it concerned medical research 
in general in a public research institute or therapy development in a drug/biomedical 
firm. The proportion of people who said they would not give their samples for 
research reflected a similar bias towards Finnish research: 6 per cent for medical 
research in public institutes, 4 per cent for therapy development in Finnish firms, 16 
per cent for international medical research and 20 per cent for therapy development in 
international firms. The rest said they weren’t sure or would not give their samples to 
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a national biobank at all (the proportions for the different alternatives varied between 
14 and 33 per cent.  
 











(number) (238) (257) (348) (345) (1188)  
(Q6) Use of own samples for joint research 
with industry, yes, % b 
73 73 75 78 75 .726 
(Q17) Use of own samples in biobanks for, 
yes, % c 
      
   medical research in (Finnish) public  
      institutes 
81 78 79 75 78 .329 
   international medical research 53 47 49 48 49 .355 
   therapy development in Finnish firms 72 78 80 79 78 .021 
   therapy development in international 
firms 
42 38 42 46 43 .360 
(Q10) Use of old clinical samples without 
consent for, yes, % d 
      
   medical research in public institutes 68 64 70 69 68 .324 
   therapeutic research in Finnish firms 55 64 66 69 64 .001 
   therapeutic research in international  
       firms 
31 30 41 43 37 .000 
(Q2) Very high or rather high trust on        
   universities, %  81 79 78 69 76 .004 
   National Public Health Institute 49 53 52 45 49 .165 
   Finnish drug firms 59 56 48 46 51 .004 
   International drug firms  34 26 25 25 27 .070 
   Private drug research firms 31 23 22 22 24 .051 
a: Q = question number, questions are given in Appendix 
b: n = 1182 
c: n = 1115-1159  
d: n = 1132 
 
When asked whether clinical samples stored in a biobank could be used for research 
without asking permission from the patient (question 10 Appendix), 68 per cent 
indicated that they would permit this for medical research in public institutes (such as 
universities or hospitals; see Table 3). The question did not define domestic research, 
but the formulation of the question implicitly suggested domestic research. Almost as 
many (64 per cent) would allow usage for developing drugs or other treatments by a 
Finnish drug or biotechnology firm. Far fewer (37 per cent) would allow their samples 
to be used for therapy development in international firms. The attitudes towards use of 
clinical samples in medical research in public institutes were similar across the age 
range (Table 3). Older people had somewhat more positive attitudes towards therapy 
development both in Finnish and international firms. 
 
In a separate question (Question 2, Appendix) we asked about trust in various 
institutions, including those shown in Table 3. Most people said they trusted 
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universities (Table 3) and public hospitals (73 per cent; not shown in the table). The 
least trust was expressed in international pharmaceutical firms and private drug 
research firms; Finnish pharmaceutical firms were in between. People in the oldest 
age group were the most likely to choose a "cannot say" option; otherwise the age 
differences in regard to public institutions were small. Younger people had somewhat 
more trust in commercial actors. Of those not choosing the trust-option, most chose 
"cannot say" while low trust (very or quite low) was chosen less frequently: 5 per cent 
for universities, 10 per cent for the national public health institute, 15 per cent for 
Finnish pharmaceutical firms, 20 per cent for private drug research firms, and 22 per 
cent for international pharmaceutical firms. 
 
Gender and education 
Tables 2–3 show results by age. We also studied whether attitudes varied by gender 
and education. These (unadjusted) cross-tabulations showed that men’s and women’s 
responses were similar (data not shown). Likewise, the responses varied only a little 
by education (Table 4). People who had undertaken higher education were more likely 
to allow their samples to enter a biobank to be used for medical research in (Finnish) 
public institutes and international medical research (Question 17 Appendix). 
However, the pattern between the different uses remained similar across all 
educational groups, with respondents favoring Finnish users over international ones. 
 
Table 4. Variation of attitudes by education: proportion of respondents agreeing to their 




middle level < 9 years 
(n) (278) (418) (484) 
Medical research in Finnish public 
institutes 
1.00 0.71 (0.52-0.98) 0.59 (0.40-0.86) 
International medical research 1.00 0.76 (0.58-0.99) 0.62 (0.44-0.87) 
Therapy development in Finnish firms 1.00 1.22 (0.90-1.67) 0.91 (0.62-1.35) 
Therapy development in international 
firms 
1.00 1.02 (0.78-1.34) 1.06 (0.75-1.49) 
 
Age-adjustment had little effect on the results by gender and education. Men's and 
women's responses were relatively similar, but some indicators suggested more 
support for biomedical research among men than women. If there were differences by 
education, people who had been through higher education tended to have more 
favourable attitudes.  
Discussion 
This population-based survey among Finnish adults showed a generally positive 
attitude towards biomedical research, with little variation by population groups but a 
strong variation according to who were the sponsors of the research. Domestic 
research was looked at more positively than international research. Whether research 
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Any interpretation of our results should take into account the unfamiliarity of the 
respondents with the topic, and the relatively low response rate. The main focus of the 
survey was biobanks. The relatively large number of people choosing “do not know” 
and “cannot say” options in regard to the explicit question eliciting whether people 
were familiar with the term ‘biobank’ suggest that the world of biomedical research is 
not very familiar to Finnish laypeople. Nine per cent of the respondents reported that 
they knew what a biobank was, 45 per cent had heard about it, but did not know how 
it operated, and 46 per cent did not know what it was.16 However, we anticipated this 
and most questions (all referred to in this paper) were formulated in such a way that 
they measured attitudes and did not require exact prior knowledge. Furthermore, 
explanations of terms were given when appropriate. 
 
Only half of the people approached responded. A similarly low response rate was 
found in a population survey in Sweden.17 Even though the gender and age 
distributions were relatively similar to the target sample, the respondents may have 
differed by other characteristics relating to attitudes towards biomedical research. The 
low response rate may also indicate that the question of biobanks and the use of 
(already collected) samples in research are not major issues to laypeople. 
 
The respondents were very positive towards biomedical research that was aimed at 
developing new medical technology (diagnostics, drugs and vaccines). That extended 
also to genetic research. Furthermore, most were willing to let their own clinical 
samples be used for later research, if asked. Previous studies have also found that 
most people do not object to the use of their clinical samples for research.18,19 
However, the low proportion of respondents in our study who considered it to be a 
duty to participate in biobanks, rather than doing it to benefit future generations or 
research, is in contrast to an earlier Japanese study in which participants frequently 
expressed an obligation to participate.20  
 
Stated reasons for giving blood samples to a biobank were more often altruistic than 
directly self-beneficial, but it was considered as “a favor to society” rather than a 
duty. That altruistic motives are more common has been found previously in clinical 
trials in Finland.21 In another study, most Finns considered genetic testing to be 
acceptable because of the potential efficiency savings for society in treating 
patients,22 while studies in Scotland have shown that participation in biobank research




Several questions indicated that the respondents were not indifferent to who was 
carrying out the research. Roughly, the dividing line was between Finnish (domestic) 
and international sponsors, rather than between public and private sponsors. Research 
by Finnish sponsors was looked at more favourably than that by international 
sponsors, even though we had used the neutral words “Finnish” and “international” 
rather than “domestic” and “foreign” This pattern was repeated when trust in different 
institutions was asked about. In an earlier study on genetic databases in Sweden, 
respondents were more trusting towards public than private institutions that handled 
and collected genetic material.24 
 
 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2009, Vol.5, No.2, pp.67-79 
 
_____________    
 
Genomics, Society and Policy, Vol.5, No.2 (2009) ISSN: 1746-5354 
74
 
The distinction between domestic and international research is certainly blurred,25 due 
to joint projects and to the multinational ownership of firms. Furthermore, research 
applicability is not tied to the country of research: innovations made in one country 
can be used in all countries. Perceptions are likely to be crucial. Thus, trust may not 
relate to the actual worthiness of the researchers in one’s own country, but to the fact 
that they live in your own country. Our survey cannot explain the higher trust in 
domestic research, but it may relate to a feeling of control. The greater trust in Finland 
in Finnish researchers has previously been found in regard to genetics research26 and 
to the SARS-epidemic.27 In general, Finns still trust society to work for their benefit 
and social capital is high.28 Participating in biobanks and biomedical research can be 
regarded as a contribution to the promotion of national public health. This links the 
altruistic motivation to domestic sponsorship – expectations that Finnish research will 
further national public health more than will international research. 
 
Earlier studies from Australia and Sweden have reported, unlike our study, that people 
look more favorably on research in public rather than in private institutions.29 No 
previous studies on how people differentiate between domestic and international 
research were found. But in a later study in Finland using focus group interviews, 
differences did emerge in relation to responses.30 Clearly only further study in other 
countries will clarify whether this is a Finnish peculiarity or a more general view. 
 
Our results suggest that people want to choose whether to be research participants, 
and to choose whom to help. The importance of choice has also been reported in 
earlier research from Scotland.31 This gives a different view from some currently 
accepted principles of medical ethics, which emphasize the protection of the research 
participants, and the benefits the participants may receive from a study. Participants’ 
desire for choice has an impact on the way participants are informed and in the criteria 
used by ethics committees and other research regulators. If participants’ usual 
common motive is altruistic, but selective, then data relevant to that should be 
provided in patient recruitment leaflets. Research participants may want honest and 
detailed information about the purpose and assumed value of the research or data 
collection - who are the researchers and sponsors, and what are their relations - as 
well as whether the results are made available for the common good. To have more 
control, research participants are likely to expect transparency in actions and access to 
research results. Whether such an approach also influences the number of people 
wanting to join research remains to be seen.32 
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Appendix 1. Questions used in the study.  
 
Q1  Are the following institutions or concepts familiar to you?  No; have heard, but do 
not know what they do; yes 
Ministry of Social Affairs and Health (STM) 
National Public Health Institute (KTL) 
The Social Insurance Institution (KELA) 
STAKES 
National Authority for Medicolegal Affairs (TEO) 
Biobanks 
Research ethics committee 
 
Q2  Below, a number of institutions that conduct medical research, develop medicines 
or offer medical and healthcare services are listed.  How much trust do you have 




Public health care centers 
Private healthcare 
National Public Health Institute 
STAKES 
Finnish pharmaceutical companies 
Private pharmaceutical companies 
International pharmaceutical companies 
 
Q3  What is your attitude towards the following types of research?  Mostly positive; 
quite positive; hard to say; quite negative; mostly negative. 
Research on human genetics/ genes 
Development of diagnostics 
Development of new medications 
Development of new vaccines 
 
Hypothetical case 1. (used in questions 5 and 6): In the following a hypothetical 
situation during a routine visit to a doctor is presented.  How would you act in that 
situation? 
"Let's assume that a blood sample is taken from you during a routine visit to a doctor. 
The nurse asks you whether the sample can also be used for scientific research. The 
sample is given a code number.  All the information from the samples is recorded. 
With the aid of the code number and your personal ID number the recorded 
information can be connected to your health records and heath register data. A public 
research institute is responsible for storing these data. The code and the personal ID 
number are stored in a safe. The data will be used to study how genes and other 
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Q5  Would you give permission for the sample to be used in research?  Yes; no; can’t 
say; explanation 
 
Q6  Sometimes researchers collaborate with companies to develop new medicines and 
treatment methods.  Could the sample taken from you be used for such collaboration?  
Yes; no; can’t say 
 
Definition of biobank (given before Q8: What is a biobank?) Blood and other tissue 
samples are called biological samples. A biobank can be formed from these kinds of 
biological samples. In the biobank, other information can be added to the samples; 
such information can be of persons' health, health behavior, living habits or care they 
have received. Samples in a biobank are used in medical research and to develop 
drugs and other care methods. 
 
Q10  Health care is required by law to store samples taken for diagnostic purposes. It 
has been estimated that millions of samples have accumulated in the archives of 
hospital districts. For which purposes could these old samples be used without asking 
for patients' consent?  Yes ; no ; can’t say 
Only for the original purpose (for diagnosis) 
Medical research in public institutions (such as universities and public hospitals) 
For solving crimes 
For determining family relations 
For developing medicines and treatments in Finnish pharmaceutical and biotechnical 
firms 
For developing medicines and treatments in international firms 
 
Hypothetical case 2 (used in questions 15 and 17). Think of a situation when a 
national biobank is being planned to be founded in Finland. It would collect samples 
of Finns originally taken for diagnosis and research.  Information from health and 
other registers would be connected to these samples. The possibility to combine the 
sample and personal information increases the value of the samples in research. The 
samples and their data could later be used to develop medicines and treatment 
methods. 
 
Q15  If you would give permission to use your samples, what would be your most 
important reasons for doing so? (You may choose more than one option.) 
Promotion of medicine 
Duty 
Identification of my risks 
Increasing international competitiveness of Finnish researchers 
Benefits for future generations  
Promotion of business  
I would be afraid to decline 
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Q17  For what purposes could your samples in the biobank be used?  Yes ; no ; can’t 
say ; I would not give my samples 
All types of medical research in public institutions (such as universities and public 
hospitals) 
International medical research 
For developing medicines and treatments in Finnish pharmaceutical and biotechnical 
firms 
For developing medicines and treatments in international firms 
 
Q19  In the following we present some claims. Circle the answer which best describes 
your opinion.  Yes; no; can’t say 
The information from my sample can be connected with my other health information 
(e.g. to my medical records). 
My samples can be used in future research, which was not anticipated at the time of 
taking the sample. 
People have a duty to donate their samples to the national biobank, because the 
benefits will accrue to all. 
People must have the right to check for which type of research their samples are being 
used. 
Dead peoples' samples can be used without specific permission. 
If the parent consents on behalf of his/her child to use the child’s samples, a new 
permission from the child has to be obtained when he/she turns 18 years. 
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